Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

News

Vaccine changes follow budget

Posted 6 May 2016

Changes to the national immunisation schedule foreshadowed earlier this week in the budget have been actioned.

Sanofi's FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion) and MSD's Zostavax, which is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older, have been added to the program and the dosing schedule for GlaxoSmithKline's HPV vaccine Cervarix has been amended.

Cervarix can now be provided to females who are at least 12 years old but less than 14, while Zostavax has been funded for immunocompetent patients who are 70 years of age or are at least 71 and less than 80 years of age and present for vaccination before 1 November 2021.

FluQuadri will be available under the NIP for people at least 65 year old, Aboriginal and Torres Strait Islanders who are aged over 15 or between three and five years and children with certain health conditions.

The addition of FluQuadri and the dosing changes to Cervarix, which bring it into line with MSD's Gardasil, were among announcements made in Tuesday's budget.

Nick Lush
nick.lush@lushmedia.com.au

Comment
Budget hopes slip sliding away
Drought, fire and now virus cut chance of PBS relief.
Top of the Hill
It's not easy going green
Don't do it for the accolades; do it for your kids.
Approvals Action
GSK's vax in a tube
New forms of rotavirus vaccine Rotarix.